Background. Sarcopenia or loss of skeletal muscle mass is an objective measure of frailty associated with functional impairment and disability. This study aimed to examine the impact of sarcopenia on surgical complications and survival outcomes in patients with endometrial cancer. Methods. A retrospective review of endometrial cancer patients who underwent surgery between 2005 and 2009 was performed. Sarcopenia was assessed on preoperative computed tomography (CT) scan by measurement of the lumbar psoas muscle cross-sectional area and defined as any value below the median (\4.33 cm 2 ). Sarcopenic obesity was defined as sarcopenia plus a body mass index (BMI) of 30 kg/m 2 or higher. Microsatellite instability (MSI) was analyzed using the National Cancer Institute (NCI) consensus markers and tumor from hysterectomy specimens. Results. Of 122 patients, 27 (22 %) met the criteria for sarcopenic obesity. Sarcopenic patients were older than patients with normal muscle mass (mean age, 69.7 vs. 62.1 years; p \ 0.001), had a lower BMI (31.1 vs. 39.4 kg/ m 2 ; p \ 0.001), and had more comorbidities (p = 0.048). Sarcopenia was not associated with tumor MSI, hospital stay, 90-day readmission rate, or early/late complications. Patients with sarcopenia had a shorter recurrence-free survival than nonsarcopenic patients (median 23.5 vs.
ABSTRACT
Background. Sarcopenia or loss of skeletal muscle mass is an objective measure of frailty associated with functional impairment and disability. This study aimed to examine the impact of sarcopenia on surgical complications and survival outcomes in patients with endometrial cancer. Methods. A retrospective review of endometrial cancer patients who underwent surgery between 2005 and 2009 was performed. Sarcopenia was assessed on preoperative computed tomography (CT) scan by measurement of the lumbar psoas muscle cross-sectional area and defined as any value below the median (\4.33 cm 2 ). Sarcopenic obesity was defined as sarcopenia plus a body mass index (BMI) of 30 kg/m 2 or higher. Microsatellite instability (MSI) was analyzed using the National Cancer Institute (NCI) consensus markers and tumor from hysterectomy specimens. Results. Of 122 patients, 27 (22 %) met the criteria for sarcopenic obesity. Sarcopenic patients were older than patients with normal muscle mass (mean age, 69.7 vs. 62.1 years; p \ 0.001), had a lower BMI (31.1 vs. 39.4 kg/ m 2 ; p \ 0.001), and had more comorbidities (p = 0.048). Sarcopenia was not associated with tumor MSI, hospital stay, 90-day readmission rate, or early/late complications. Patients with sarcopenia had a shorter recurrence-free survival than nonsarcopenic patients (median 23.5 vs.
32.1 months; log-rank p = 0.02), but did not differ in terms of overall survival (log-rank p = 0.25). After adjustment for race, BMI, lymphocyte count, and tumor histology, sarcopenia was associated with a fourfold shorter recurrence-free survival (adjusted hazard ratio [HR adj ], 3.99; 95 % confidence interval [CI], 1.42-11.3). Conclusions. Sarcopenia has an impact on recurrence-free survival, but does not appear to have a negative impact on surgical outcomes or overall survival among endometrial cancer patients who undergo preoperative CT scan.
The association of malnutrition with adverse clinical outcomes is well established in the literature and was recognized as early as 1936 by Studley.
1 Although validated screening tools exist to aid recognition of malnutrition, 2, 3 their clinical adoption has been underutilized, and recognition of patients with malnutrition and those at high risk for malnutrition remains poor. Other markers of nutritional status such as serum protein concentrations and lymphocyte counts also have been investigated. However, to date, no universally accepted index of nutritional status exists that predicts length of hospital stay or mortality.
More recently, interest in studying the relationship of body composition to cancer incidence and outcomes has grown. Sarcopenia (sarco = ''muscle,'' penia = ''lack of'') or loss of skeletal muscle mass is an objective measure of frailty associated with functional impairment and disability. 4 Historically, sarcopenia was defined as muscle mass greater than two standard deviations below that of healthy adults. 5, 6 However, with more advanced methods of in vivo body composition using dual-energy X-ray absorption (DEXA), magnetic resonance imaging (MRI), and computed tomography (CT) scans, the definition of sarcopenia has continuously evolved without much consensus. Nonetheless, the clinical implications of sarcopenia have been consistently associated with a longer hospital stay, 7, 8 higher costs of care, higher risk of nosocomial infections, 9 and decreased survival in both nonmalignant 4,10 and malignant conditions. [11] [12] [13] [14] [15] [16] [17] Sarcopenia also has been shown to have a negative impact on patients undergoing surgery 3, 18, 19 and to be a significant predictor of chemotherapy toxicity. 20 Despite this growing body of literature, the impact of sarcopenia among gynecologic oncology patients has yet to be elucidated.
The overall purpose of this study was to examine the impact of sarcopenia on surgical complications and overall morbidity and mortality among patients with endometrial cancer. The specific study objectives were twofold. First, we aimed to assess the clinical implications of sarcopenia for predicting the risk of surgical complications and overall prognosis of patients with endometrial cancer. Second, we hoped to contribute novel data, not only by studying sarcopenia in this specific cancer population, but also by analyzing the relationship, if any, between specific molecular endometrial tumor markers (e.g., microsatellite instability [MSI]) and sarcopenia, for the purpose of enhancing perioperative counseling regarding clinical outcomes. We hypothesized that sarcopenia is associated with increased surgical morbidity and disease mortality in patients with endometrial cancer. We also postulated that patients with sarcopenia and MSI may have lower survival rates than nonsarcopenic patients with microsatellite stability.
METHODS
We performed a single-institution, retrospective review of 122 women with a diagnosis of endometrial cancer between 2005 and 2009 who had a preoperative CT scan. Before initiation of the study, all procedures were reviewed and approved by Washington University's Human Research Protection Office (HRPO #201204131). Data extracted from patients' charts and electronic medical records included demographic information, physical exam findings, laboratory results, radiographic imaging, operative reports, pathology, and tumor markers. We excluded patients with recurrent disease and those who did not have a preoperative CT scan within 60 days before surgery. We confirmed all diagnoses by documented histology on pathology reports.
Sarcopenia was defined as muscle mass below the median (\4.33 cm 2 ) on preoperative CT scan. Muscle mass was assessed by psoas muscle density and total psoas area. The third lumbar vertebra (L3) was chosen as the standard landmark, 21, 22 and an average of left and right sides was calculated. The psoas muscle was manually outlined, and the cross-sectional area for muscle and adipose tissue was reported (cm 2 ) and normalized for stature (cm 2 /m 2 ). All images were analyzed by a single trained observer (M.M.) within the Department of Radiology at Washington University School of Medicine in St. Louis. Estimates of whole-body stores were generated using the following regression equations by Mourtzakis et al. 21 which showed a close correlation (r value) between muscle and fat areas in CT images at the third lumbar vertebrae and whole-body compartments of fat-free mass and fat mass, respectively:
Total body fat-free mass kg ð Þ ¼ 0:3
Total body fat mass kg ð Þ ¼ 0:042
The patients were classified as obese (body mass index
2 ) or nonobese based on measurements taken on the date of their appointment at the Center for Preoperative Assessment and Planning or on the day of surgery. Preoperative factors included age, race, weight, BMI, complete blood count (CBC), American Society of Anesthesiologists (ASA) score, and Adult Comorbidity Evaluation (ACE) score from the Cancer Center Registry at Washington University School of Medicine in St. Louis, Missouri.
Postoperatively, we collected data on tumor histology from pathology reports and tumor markers from an institutional review board (IRB)-approved database within the Division of Gynecologic Oncology at Washington University School of Medicine in St. Louis, Missouri. We also accessed patient operative reports to determine the type of surgery performed. Other outcome variables evaluated included postoperative complications, length of hospital stay, 90-day readmission for surgical complication, recurrence-free survival (RFS), and overall survival (OS).
Preoperative characteristics, disease characteristics, radiographic features, and clinical outcomes were compared using Fisher's exact test, Student's t test, or the Wilcoxon rank-sum test depending on the type of variable and its distribution. Time to recurrence was defined as the time from the date of surgery to physical or radiographic evidence of disease recurrence. RFS was the time from surgery to physical or radiographic evidence of disease recurrence or the date of the last contact if no recurrence occurred. Patients alive without disease recurrence were censored at the date of last contact. Overall survival was defined as the time between the date of surgery and the date of death or the date of last follow-up assessment. The Kaplan-Meier method was used to estimate survival times, and distributions were compared using the logrank test. Multivariable survival analyses considered the following variables as potential confounders: age, race, BMI, lymphocyte count, ASA score, ACE score, all histologic types (e.g., endometrioid, papillary serous, clear cell, and mixed), stage of disease, and MSI markers. However, only four of these variables (race, BMI, lymphocyte count, and histology) resulted in a more than a 10 % change in the estimate of effect for sarcopenia and were therefore adjusted for in the multivariable models. Unadjusted and adjusted Cox proportional hazards models were estimated for RFS and OS separately. The alpha for all analyses was set at 0.05.
RESULTS
Our study included 122 endometrial cancer patients with a mean age of 65.9 ± 10.4 years and a mean BMI of 35.3 ± 10.2 kg/m 2 ( Table 1 ). The majority of the patients had grade 3 (40 %) stage 1 or 2 (72 %) disease, with corresponding histology confirmed as endometrioid (72 %), followed by mixed (18 %), papillary serous (8 %), and clear cell (2 %). The mean lumbar total muscle crosssectional area was 4.5 cm 2 , and the total body fat-free mass was 7.4 kg. Given our predefined criteria of sarcopenia as psoas muscle mass below the median (\4.33 cm 2 ), 61 patients (50 %) were sarcopenic based on their lumbar cross-sectional area, and 27 patients (22 %) met the criteria for sarcopenic obesity.
Patients were divided into two groups: those with sarcopenia versus those with no sarcopenia (Table 1) .
Among the preoperative factors analyzed, race, height, ASA score, and lymphocyte count did not differ significantly between sarcopenic and nonsarcopenic patients. However, compared with nonsarcopenic patients, those with sarcopenia were older (p \ 0.001), had a lower BMI (p \ 0.001), and had more comorbidities, as represented by higher ACE scores (p = 0.048). The radiographic features including lumbar total muscle cross-sectional area (p \ 0.001), lumbar skeletal muscle index (p \ 0.001), estimated total fat-free mass (p \ 0.001), and body surface area (BSA) (p \ 0.001) all were significantly lower among those with sarcopenia. No tumor features (e.g., histologic type, grade, stage, or MSI) or clinical/surgical outcomes (Table 2 ) differed between sarcopenic and nonsarcopenic women.
Kaplan-Meier analysis comparing sarcopenic and nonsarcopenic patients showed a shorter time to recurrence among the endometrial cancer patients with sarcopenia (log rank p value = 0.02; Fig. 1a ), but no significant difference in OS (log-rank p value = 0.25; Fig. 1b) . We performed multivariable regression using a Cox proportional hazards models, adjusting for potential confounders (e.g., race, BMI, lymphocyte count, and tumor histology), which resulted in more than a 10 % change in the estimate of effect for sarcopenia. Sarcopenia was associated with quicker recurrence (hazard ratio [ (13) 11 (18) 5 (8) Col % and row % signifies that the percentages are calculated from either column totals (n = 122) or row totals (n = 61) respectively BMI, body mass index; ASA, American Society of Anesthesiologists; ACE, Adult Comorbidity Evaluation; CT, computed tomography a All p values were estimated from Fisher's exact test b Open procedure includes total abdominal hysterectomy ± bilateral salpingo-oophorectomy (BSO); minimally invasive surgery includes robotic-assisted total laparoscopic hysterectomy (TLH), TLH, and laparoscopically assisted vaginal hysterectomy ± BSO
DISCUSSION
To our knowledge, this study is the first to investigate the role of sarcopenia in endometrial cancer patients and to demonstrate a high prevalence of sarcopenic obesity (25 %) in this population. The ability of cancer to induce muscular atrophy complicates the interplay between sarcopenia and obesity. However, endometrial cancer patients are a particularly interesting population to study given that obesity is a highly prevalent and well-established risk factor for endometrioid carcinomas. Furthermore, the association we demonstrated between sarcopenia and an increased number of medical comorbidities provides an area for improved perioperative counseling. Sarcopenia predicted decreased RFS, but multivariate analysis showed no significant impact on OS. This may have been due to the limitations of our small sample size and the number of deaths that occurred during the study period. Col % and row % signifies that the percentages are calculated from either column totals (n = 122) or row totals (n = 61) respectively a n represents the number of patients who experienced a complication. The subcategories of specific complications are not mutually exclusive because the patients may have had more than one complication b p value from the Wilcoxon rank sum test of difference in medians Sarcopenia is a phenomenon of aging, and within our population of endometrial cancer patients, we confirmed that sarcopenic patients were older by 7.6 years. However, we did not adjust for age in the multivariable analysis because age did not result in more than a 10 % change in the estimate of effect for sarcopenia in the model for RFS or OS. Nonetheless, we recognized age as a strong predictor of sarcopenia and therefore ran a separate multivariate analysis including age (as a continuous variable) to assess whether the effect of sarcopenia on RFS and OS would diverge from the model without age. Essentially, the models showed insignificant differences for RFS (HR, 3.70 vs HR adj , 3.99) and OS (HR, 1.79 vs HR adj , 1.98). This suggests that age may not have had a large confounder effect due to the narrow age range in our study population, giving us a rather homogeneous population of older patients with endometrial cancer.
Although our study was dedicated to investigating the impact of sarcopenia on endometrial cancer patients, in general, sarcopenia is becoming more prevalent and is appropriately being studied across medical disciplines. Unfortunately, published studies currently show inconsistent findings. Prado et al. 20 studied sarcopenia as a determinant of chemotherapy toxicity for patients with metastatic breast cancer receiving capecitabine. These authors showed that toxicity was present in 50 % of the sarcopenic patients versus 20 % of the patients with normal muscle mass (p = 0.03). The time to tumor progression was shorter for the sarcopenic patients by 72 days (p = 0.05). Contrary to these results, Awad et al. 23 demonstrated no associations between sarcopenia and loss of fat-free mass, incomplete neoadjuvant chemotherapy, increased hospital stay, or mortality in patients with esophagogastric cancer.
These inconsistencies may stem from the lack of a standardized definition of sarcopenia. 24 It was initially defined as a level of muscle mass two standard deviations below sex-specific norms for young adults. 5, 6 However, the majority of published studies use arbitrary criteria that are study specific, with some studies using imaging modalities such as CT or DEXA scans and others basing their criteria on muscle strength due to the cost effectiveness of the measurements. 24 Newer data within the realm of oncology suggest that the CT cross-sectional area at L3 is strongly related to the appendicular skeletal mass, 13, 21 with a reported precision error of about 1.4 %. 22 Given the inconsistency of definitions, we recognized this as a limitation and chose to define sarcopenia as the mean L3 muscle mass that fell below the median (\4.33 cm 2 ). Other limitations of our study were those inherent to any retrospective design. We included consecutive patients who met eligibility criteria, and as such, the study was not powered to detect differences in clinical outcomes. Furthermore, although the study had a reasonable representation across histologic types, the study population was not evenly distributed across all stages. It would have been advantageous to have had a greater representation of advanced stage tumors because these patients are the most likely to benefit from nutritional assessment before surgery in anticipation of extensive tumor burden, prolonged operative time, higher risk for complications, and ultimate need for adjuvant therapy. Proportion experiencing death 4 5 Lumbar cross-sectional area Despite recent interest in the clinical implications of sarcopenia in the setting of cancer, the scope of available data still is limited by the type malignancy and the clinical outcomes studied. We selectively studied a high-risk population by including only patients with preoperative CT scans. However, sarcopenic obesity may have more clinical implications in a population study that includes both lowand high-risk endometrial cancer patients and warrants further investigation. Future prospective studies may benefit from investigating the relationship between other tumor markers associated with type 1 endometrial cancers and sarcopenia in order to better counsel patients regarding their perioperative risks and overall disease prognosis.
Evidence suggests that genetic mutations in phosphatase and tensin homolog (PTEN, 60-80 %) and Kristen rat sarcoma viral oncogene homolog (K-ras) as well as MSI mutations, often coexist with each other 25 and are more prevalent among patients with endometrioid histology. 26 Risinger et al. 27 specifically studied the clinical implications of PTEN mutations for endometrial cancer and showed correlations between this tumor suppressor gene and early-stage, nonmetastatic disease. Such data provide more avenues of investigation for further study of the relationship between sarcopenia and these common tumor markers and their impact on surgical and survival outcomes.
Extrapolating from the current body of literature, sarcopenia and sarcopenic obesity may have clinical implications in gynecologic oncology beyond endometrial cancer patients, warranting further investigation. We hope our results serve as a platform for future studies, especially given the increasing prevalence of sarcopenia among older patients and the growing trend of obesity in the United States. It is a potential modifiable risk factor that should be addressed during preoperative counseling so that patients are well informed and may choose to adjust their lifestyle to optimize their health before undergoing treatment.
